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The aim of this study was to investigate the awareness and experience,  among dental practitioners,  of adverse 
events resulting from dental treatment of patients undergoing therapy with drugs that affect the immune system 
[angiogenesis inhibitors,  biological agents,  immunosuppressants,  and disease-modifying anti-rheumatic 
drugs (DMARDs)].  For this purpose,  a nationwide questionnaire survey was conducted.  Questionnaires were 
sent to 2,050 dentists,  of which 206 (10.1%) were completed and returned.  The results showed that most den-
tists were aware of complications associated with dental treatment of patients treated with drugs that affect the 
immune system,  and about half had actually experienced such complications.  Delayed wound healing,  osteo-
necrosis of the jaw (ONJ),  and postoperative infections were reported.  Whereas approximately 50% of dentists 
did not discontinue the drugs during dental treatment,  about 18% did.  During temporary drug discontinua-
tion,  some patients experienced aggravation of the primary disease,  such as worsening of rheumatism,  growth 
of tumors,  and rejection reactions of transplanted organs.  As for medical cooperation,  only less than half of the 
dentists were asked for oral hygiene management by a physician prior to starting the drug treatment.  
Prospective studies are needed because evidence for dental treatments in patients treated with these drugs 
remains limited.
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O steonecrosis of the jaw related to drugs (called medication-related osteonecrosis of the jaw:  
MRONJ) has often been reported in patients taking 
antiresorptive agents,  such as bisphosphonates (BPs) 
and anti-receptor activator of nuclear factor κB ligand 
(anti-RANKL) denosumab.  The prevalence of ONJ in 
Asian patients prescribed oral BPs for osteoporosis has 
been found to range from 0% to 0.094%,  and that of 
low-dose intravenous BPs was 0-0.348% [1 , 2].  The 
incidence of ONJ in patients receiving oral BPs and iv 
BPs was 1.04-69 per 100,000 patient-years and 0-90 per 
100,000 patient-years,  respectively [2].  However,  
Taguchi et al.  reported a high incidence of Stage 0 or 
Stage 1 ONJ of 6.14 per 1000 patient-years in osteopo-
rosis patients with good oral health receiving mino-
dronic acid [3].  The incidence of ONJ in patients pre-
scribed denosumab ranged from 0 to 30.4 per 100,000 
patient-years [2].
Numerous studies have been conducted on the onset 
of osteonecrosis of the jaw (ONJ) and its prevention and 
treatment during oral and maxillofacial surgical proce-
dures (e.g.,  tooth extractions) in patients with osteopo-
rosis or malignant tumors receiving treatment with 
drugs such as antiresorptive agents.  Position papers 
have been published in the United States and Japan 
[4 , 5].  Both of these papers suggested that antiresorp-
tive drugs do not have to be discontinued before tooth 
extraction,  or they can be discontinued for 2 months 
before tooth extraction when needed [4 , 5].  In addition 
to these drugs,  corticosteroid hormones and new drugs 
(e.g.,  disease-modifying antirheumatic drugs [DMARDs],  
biological agents,  immunosuppressants,  angiogenesis 
inhibitors) have been used in rheumatic medicine,  
transplantation therapy,  and the treatment of tumors in 
recent years,  and reports of complications associated 
with dental treatments related to infections,  delayed 
wound healing,  and ONJ have occasionally been 
reported [6-8].  The United States Food and Drug 
Administration (FDA) published a warning on the risk 
of MRONJ with the use of the angiogenesis inhibitors 
bevacizumab and sunitinib [4-6 , 8 , 9].  There are reports 
of other drugs causing complications such as ONJ;  
however,  there is currently a lack of evidence about 
complications associated with dental treatments in 
patients undergoing therapy with drugs that affect the 
immune system [7].
In order to suppress the occurrence of complications 
related to dental treatment in patients receiving these 
drugs,  cooperation between medical physicians and 
dentists is necessary.  Dental practitioners are generally 
thought to be well-informed regarding bone resorptive 
inhibitors,  based on the position papers cited above and 
the curricula of dental practitioner programs.  However,  
a questionnaire survey targeting physicians reported 
that there is insufficient cooperation between physicians 
and dentists,  and some complications (such as fracture) 
were observed [10].  At the same time,  dentists have not 
been actively informed about drugs other than bone 
resorptive inhibitors.
The aim of the present study was to investigate the 
awareness of and experience with adverse events result-
ing from dental treatment of patients receiving these 
new drugs that affect the immune system.  For this pur-
pose,  a questionnaire survey was conducted targeting 
dental practitioners,  including oral and maxillofacial 
surgeons and general dental practitioners.  The out-
comes could contribute to the establishment of new 
strategies to disseminate management policies about 
these complications to all dentists.  The findings of this 
questionnaire survey are reported in the present study.
Materials and Methods
This study was conducted in accordance with the 
Helsinki Declaration.  The present questionnaire survey 
was planned by the survey and research-planning com-
mittee of the Japanese Society of Dentistry for Medically 
Compromised Patients and was conducted after obtain-
ing approval from the Society’s ethics committee (No.  
6) and Board of Directors.  An outline of the items in 
the questionnaire survey is presented below.
1.  The items consisted of the following questions:
　(1)  To what affiliation and division do you belong?
　(2) What are your major specialties?
2.   Did you know that complications associated with 
dental treatment can occur in patients treated 
with drugs that affect the immune system?
3.   Have you ever seen complications associated with 
dental treatments in patients treated with drugs 
that affect the immune system?
4.  Could you describe the cases you have seen?
　(1)  What kind of drugs that affect the immune 
system were used?
　(2)  For how long were the drugs that affect the 
immune system used before the dental treat-
ments?
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　(3)  What kinds of complications were observed?
　(4)  What kinds of dental treatments contributed to 
the complications?
　(5)  How long after the dental treatments were per-
formed were the complications observed?
5.   Did you ask the physician to discontinue or change 
the drugs that affect the immune system before 
the dental treatments?
　(1)  What kinds of drugs that affect the immune 
system did you ask the physicians to discon-
tinue or change?
　(2)  For how long were the drugs that affect the 
immune system discontinued?
　(3)  What kinds of complications did you observe 
during the discontinuation of drugs that affect 
the immune system?
　(4)  Were the drugs restarted after the dental treat-
ments?
　(5)  If you did not ask to discontinue the drugs,  
please provide the reasons.
6.   During tooth extractions,  were any findings of 
acute inflammation observed around the teeth?
　(1)  Did you prescribe antibiotics when you per-
formed invasive treatments?
　(2) What kinds of antibiotics did you prescribe?
7.   Is it your experience that physicians consult with 
dentists about oral hygiene treatment before 
medical treatment?
8.   Is it your experience that patients treated with 
drugs that affect the immune system ask about the 
complications associated with dental treatments?
9.   Do dentists cooperate with physicians in regard to 
the medical care in your region?
10.   Do you cooperate with physicians in regard to 
this medical care?
The questionnaire survey targeted 2,050 dentists 
who were members of the Japanese Society of Dentistry 
for Medically Compromised Patients and the Japanese 
Society of Hospital Dentistry and Oral-Maxillofacial 
Surgery.  The study period was between December 2017 
and February 2018.  The questionnaires were mailed by 
the Society’s Secretariat,  and the completed question-
naires were returned by mail in the enclosed self- 
addressed stamped envelopes.  Database entry of the 
collected questionnaires was conducted by the 
Department of Dentistry and Oral Surgery at Shinshu 
University School of Medicine,  and the data were pro-
cessed in the Department of Critical Care Medicine and 
Dentistry at Kanagawa Dental University Graduate 
School of Dentistry.  The drugs that were studied (drugs 
affecting the immune system) were angiogenesis inhib-
itors and other molecular targeted drugs,  anticancer 
drugs,  DMARDs,  biological agents,  immunosuppres-
sants,  sulfonamides,  corticosteroid hormones,  and 
antiresorptive agents (e.g.,  BPs,  anti-RANKL drugs).  
Since the number of responses varied for each question,  
the percentage (%) of the total number of responses was 
calculated for each response.  Statistical analysis was 
conducted using SPSS (ver. 16.0; SPSS Japan Inc.,  Tokyo).  
Most items were analyzed using descriptive analysis.
The questionnaires included the following message:  
“Return of the completed questionnaire will be consid-
ered consent to participate”.  Since this was an anony-
mous questionnaire that did not require the partici-
pants’ names or sex or the names of the affiliated 
institutions,  it was not considered necessary to obtain 
consent regarding the protection of personal informa-
tion.
Results
Questionnaire collection and the characteristics of 
the respondents. Of the 2,050 mailed questionnaires,  
206 were completed and returned (10.1% response rate).  
A total of 112 dentists (56.3%) were affiliated with the 
Department of Oral and Maxillofacial Surgery,  while 68 
(33.8%) worked in dental clinics and 17 (8.6%) worked 
in departments of periodontology or gerodontology.  
No responses were given by 5 dentists (Fig. 1).
The reported drugs that affect the immune system 
are listed in Table 1.
Knowledge of and experience with complications 
associated with dental treatments in patients undergo-
ing therapy with drugs that affect the immune system.
Overall,  193 dentists (97.0%) were aware of the possi-
bility of complications (such as postoperative wound 
infections,  delayed wound healing,  and ONJ) associ-
ated with dental treatments in patients undergoing 
therapy with drugs that affect the immune system.  Six 
dentists (3.0%) had no awareness.  A total of 96 dentists 
(48.2%) saw patients with complications,  whereas 103 
(51.8%) did not.  The numbers of patients with compli-
cations that dentists saw were as follows: 1 patient (9 
dentists),  2 patients (4 dentists),  3 patients (6 dentists),  
4 patients (1 dentist),  5 patients (3 dentists),  and 6 or 
more patients (4 dentists).
April 2021 Dental Complications Caused by Drugs 117
Complications associated with dental treatments in 
patients undergoing therapy with drugs that affect the 
immune system. Table 2 shows the number of 
reported cases for each drug that affects the immune 
system.  The duration of drug treatments prior to dental 
treatment is shown in Table 3; approximately half of 
participants (133 dentists; 48%) reported durations of 
less than 1 month.
Figure 2A shows the complications associated with 
dental treatment.  Delayed wound healing (35%),  ONJ 
(33%),  and postoperative wound infection (14%) were 
the most common.  While the relationship with dental 
treatments was weak,  cases of intractable stomatitis and 
oral ulcers (8%) and lymphoproliferative diseases (4%) 
were observed.
Figure 2B shows the factors associated with compli-
cations.  The dental treatments thought to be associated 
with complications were mainly tooth extractions (79 
dentists; 61%).
Table 4 shows the detailed associations between the 
drugs and complications.  Delayed wound healing (31 
dentists) and ONJ (25 dentists) were mainly observed 
with single-drug therapies.  Delayed wound healing and 
ONJ were observed with combination therapies of 
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Fig. 2　 Complications of dental treatment and factors associated 
with them.  A,  Complications of dental treatment; B,  Factors asso-














Fig. 1　 Affiliations of the responders.  The numbers indicate the 
number of dentists (percentage).
OMFS,  Department of Oral and Maxillofacial Surgery; Dentistry,  
Department of Dentistry; MUH,  Medical University Hospital; DUH,  
Dental University Hospital; GH,  General Hospital.
Table 1　 The list of reported drugs
Classification Drugs
▪　Molecular targeted drugs
　　Angiogenesis inhibitor (mammalian target of rapamycin inhibitor) Everolimus
　　Angiogenesis inhibitor (vascular endothelial growth factor inhibitor) Bevacizumab
　　Angiogenesis inhibitor (Multi-kinase inhibitor) Sorafenib,  Sunitinib
　　Anti-CD20 monoclonal antibody Rituximab
▪　Anticancer drugs Cyclophosphamide
▪　Disease modified anti-rheumatic-drugs (DMARDs) Methotrexate,  Iguratimod,  Sodium aurothiomalate,  Bucillamine
▪　Biological agents Infliximab,  Tocilizumab,  Golimumab,  Etanercept,  Adalimumab,  Abatacept
▪　Immunosuppressants Everolimus,  Cyclosporin,  Azathioprine,  Tacrolimus
▪　Sulfonamide Salazosulfapyridine
▪　Corticosteroid hormone Predonisolone
DMARDs (methotrexate or bucillamine) with various 
other drugs (infliximab or tocilizumab: 5 dentists;  
cyclosporine: 2; prednisolone: 1; bisphosphonates: 1).
The onset period of complications associated with 
dental treatments for postoperative wound infections 
and delayed wound healing was less than 1 month (7 
dentists),  1 month (23 dentists),  or 3,  4,  and 5 months 
(1 dentist each).  ONJ was observed in less than 1 
month (1 dentist),  1 month (5 dentists),  2 months (1 
dentist),  or 4 months (2 dentists).
Drug discontinuation. A total of 30 dentists 
(18.1%) asked the attending physicians to discontinue 
these drugs prior to oral and maxillofacial surgeries; 85 
(51.2%) did not make such requests.  While 44 dentists 
(26.5%) saw both kinds of cases (cases in which a dis-
continuation request was made and cases in which it 
was not made),  7 (4.2%) requested a change to another 
medication.
The drugs directed by the attending physician for 
discontinuation prior to dental treatment were metho-
trexate,  immunosuppressants,  biological agents,  
angiogenesis inhibitors,  and corticosteroid hormones 
(Table 5).  Relatively few requests were made for dis-
continuation of BPs and anti-RANKL drugs (3 dentists;  
3%) and other DMARDs (1 dentist; 1%).  One dentist 
(1%) performed dental treatment between drug inter-
vals.
The most common discontinuation period prior to 
the dental procedure was less than 4 months (Table 6).  
The discontinued drugs were reported to have been 
April 2021 Dental Complications Caused by Drugs 119
Table 2　 Drugs that affect the immune system
Drugs Number of dentists Percentage(%)
Methotrexate 50 26.2
Corticosteroid hormone 36 18.9
Angiogenesis inhibitor 28 14.7
Biological agents 23 12.0
Bisphosphonate and denosumab 20 10.5
Immunosuppressants 18 9.4
Molecular target drugs 13 6.8
Other DMARDs  2 1.0
Anticancer drugs  1 0.5
DMARDs,  Disease-modifying antirheumatic drugs.
Table 3　 Duration of drug therapy prior to dental treatment
Duration of treatment prior 
to dental treatment Number of dentists
Percentage 
(%)
≤1 month 133 48.5
>1 month,  ≤2 months  39 14.2
>2 months,  ≤3 months  21 7.7
>3 months,  ≤4 months  21 7.7
>4 months,  ≤5 months  10 3.7
>5 months,  ≤6 months  10 3.7
>6 months,  ≤7 months  13 4.7
>7 months,  ≤12 months  12 4.4
>1 year  15 5.4
There were overlapping numbers,  because multiple dental treat-
ments were performed by a dentist.
Table 4　 Complications after dental treatment associated with drugs that affect the immune system







Disease-modifying antirheumatic drugs (DMARDs) 13  9  5  4 0 18
Corticosteroid hormone  2  6  4  3 0 13
Angiogenesis inhibitor  4  8  5  1 1 15
Biological agents  1  3  4  2 0 9
Bisphosphonate agents and denosumab  0  1  6  0 0 7
Immunosuppressants  1  3  1  0 0 4
Others  0  1  0  0 0 1
Total complications - 31 25 10 1 -
Each category includes some drugs described below.
Disease-modifying antirheumatic drugs (DMARDs): methotrexate,  iguratimod,  sodium aurothiomalate,  bucillamine;
Corticosteroid hormone: prednisolone;
Angiogenesis inhibitors: bevacizumab,  sorafenib,  everolimus,  sunitinib;
Immunosuppressants: everolimus,  cyclosporine,  azathioprine,  tacrolimus;
Biological agents: infliximab,  tocilizumab,  golimumab,  etanercept,  adalimumab,  abatacept;
Bisphosphonate drugs: zoledronate,  alendronate;
Others: cyclophosphamide,  rituximab
restarted after the dental treatment by 44 dentists 
(60.3%) and terminated by 4 (5.5%),  while the status of 
the discontinued drugs is unknown for 25 dentists 
(34.3%).  The timing of resuming the drug after the 
dental treatment was usually less than 3 months (Table 
6).  All discontinuations and resumptions were deter-
mined by the attending physicians.  The following 
adverse effects were observed during the drug discon-
tinuation period: worsened rheumatism in 3 patients 
(methotrexate in 2 and methotrexate + immunosup-
pressant in 1),  enlarged tumor in 1 patient (a patient on 
bevacizumab),  rejection reaction of the transplanted 
organ in 1 patient (a patient on immunosuppressants),  
no adverse effects in 48 patients,  and unknown in 1 
patient.
The reasons for not needing to discontinue the drugs 
were: “impedes the treatment of the primary disease” 
(53 dentists; 50%); “low occurrence of infections,  etc.” 
(23 dentists; 22%); “no evidence” (17 dentists; 16%);  
“impedes dental treatment” (6 dentists; 6%); and “no 
reason” (6 dentists; 6%).
Administration of antibiotics. Prior to tooth 
extraction,  33 patients (58.9%) observed acute inflam-
mation surrounding the tooth to be extracted,  and 23 
(41.1%) observed no acute inflammation.  As for the 
administration of antibiotics for invasive dental treat-
ments such as tooth extractions,  86 dentists (94.5%) 
administered antibiotics,  3 (3.3%) did not,  and 2 were 
uncertain about whether antibiotics had been adminis-
tered (2.2%).  The types of antibiotics used were as fol-
lows: penicillin-based (48 dentists; 43%),  cephalo-
sporin-based (46 dentists; 41%),  quinolone-based (12 
dentists; 11%),  macrolide-based (5 dentists; 4%),  and 
clindamycin (1 dentist; 0.9%).  Quinolones and clinda-
mycin were used following penicillin and/or cephalo-
sporin-based antibiotics in all reported cases.
Medical cooperation. A total of 75 dentists 
(46.3%) were asked to provide oral hygiene manage-
ment by physicians prior to starting treatments with 
drugs that affect the immune system,  whereas 86 
(53.1%) did not receive such requests,  and 1 (0.6%) was 
uncertain about whether such a request had been made.  
A total of 72 dentists (40.2%) were asked by patients 
about complications associated with dental treatments 
when undergoing therapy with these drugs,  100 (55.9%) 
were not asked,  and 7 (3.9%) were uncertain whether 
they had been asked.
As for the community’s involvement pertaining to 
complications associated with dental treatments related 
to these drugs,  71 dentists (38.0%) responded that there 
was cooperation between physicians and dentists,  65 
(35.9%) said that there was no such cooperation,  and 
51 (28.2%) were uncertain as to whether cooperation 
took place.  Moreover,  142 dentists (75.9%) said that 
they were personally involved in cooperating with phy-
sicians regarding the patients undergoing treatments 
with these drugs,  19 (10.2%) were planning to do so,  
and 26 (13.9%) were not involved in such cooperation.
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Table 5　 Drugs discontinued prior to dental treatment
Drugs Number of dentists Percentage(%)
Methotrexate 34 37.8
Biological agents 14 15.6
Immunosuppressants 14 15.6
Angiogenesis inhibitor 13 14.4
Corticosteroid hormone 10 11.1
Bisphosphonates and denosumab  3 3.3
Other DMARDs  1 1.1
Dental treatment between drug 
intervals  1 1.1
DMARDs,  Disease-modifying antirheumatic drugs.
Table 6　 Drug discontinuation or resumption periods prior to/after dental treatment
Duration Number of dentists for duration of drugdiscontinuation (%)
Number of dentists for duration of drug
resumption (%)
≤1 month  6 (13.3)  3 (12.0)
>1 month,  ≤2 months 13 (28.9) 16 (64.0)
>2 months,  ≤3 months 10 (22.2)  4 (16.0)
>3 months,  ≤4 months 10 (22.2) 1 (4.0)
>4 months,  ≤5 months 1 (2.2) 0
>5 months,  ≤6 months 0 0
>6 months,  ≤7 months 3 (6.7) 0
>7 months 2 (4.5) 1 (4.0)
Discussion
The results of the present survey showed that most 
dentists were aware of the possible complications (such 
as postoperative wound infection,  delayed wound heal-
ing,  and ONJ) associated with dental treatments caused 
by drugs such as DMARDs,  biological agents,  immu-
nosuppressants,  and angiogenesis inhibitors.  In fact,  
about half of the dentists had actually seen such compli-
cations.  A questionnaire survey of general dental prac-
titioners (GDPs) in the United Kingdom found that 
over 90% of dentists were not aware that antiresorptive 
agents other than BPs (e.g.,  denosumab) and angiogen-
esis inhibitors may cause MRONJ [11].  According to 
another study,  33.6% of GDPs,  48.5% of dental radiol-
ogists,  and 84.4% of oral and maxillofacial surgeons 
(OMSs) were aware that antiresorptive agents and 
angiogenesis inhibitors may cause MRONJ [12].  It is 
not surprising that the level of awareness among the 
OMSs was high,  because most of the OMSs worked in 
hospitals in collaboration with physicians.  Awareness of 
the complications was also high in the present study,  
because the majority of the respondents were OMSs.  
This suggested the importance of increasing awareness 
and experience levels related to this matter among den-
tists in all specialties.
In regard to the period of drug use prior to dental 
treatment,  approximately half of the dentists had per-
formed dental treatments either before or immediately 
after patients started the drug treatments (less than 1 
month: 48%): in other words,  during a time period 
when the drugs were considered to have a minimal 
effect.  According to Pimolbutr et al.,  the average treat-
ment period with angiogenesis inhibitors prior to 
developing MRONJ was 6.5 months with intravenous 
drugs and 16 months with oral drugs,  and undertaking 
dental treatments prior to starting the drug treatment or 
in the early stages was considered reasonable [13].
In the present study,  complications associated with 
dental treatments were delayed wound healing (35%),  
ONJ (33%),  and postoperative wound infection (14%),  
and these accounted for 82% of all complications.  
Tooth extraction was the most frequent dental treat-
ment associated with complications,  accounting for 
approximately 60% of the cases with complications.  
Pimolbutr et al.  reported that the causes of MRONJ 
were tooth extraction (37%) and damage to the oral 
mucosa due to dentures,  dental and periodontal 
inflammation,  and the placing of implants (23%) [13].  
Fusco et al.  observed a high rate of ONJ (52%) in those 
taking a combination of primarily zoledronic acid and 
sunitinib,  and the main causes were dental and peri-
odontal infection (34%),  tooth extraction (30%),  and 
undetermined cause (28%) [14].  Ghidini et al.  found 
that,  in many cases,  tooth extraction and jaw surgeries 
were the cause of ONJ with single-drug therapy with BP,  
and with combination therapy with BP and angiogene-
sis inhibitors,  there were many spontaneous occur-
rences [15].  In the present study,  tooth extraction was 
a slightly more common cause of complications than 
reported in previous studies.  No cause or undeter-
mined cause was seen in 28% of cases,  which was simi-
lar to the rate in previous studies.  A certain number of 
spontaneous occurrences of complications were also 
observed.
Previous reports have found that MRONJ occurs 
frequently with the combined use of BP and angiogene-
sis inhibitors [13 , 14].  In the present study,  there were 
no reported cases of the combined use of BP and angio-
genesis inhibitors; however,  delayed wound healing,  
ONJ,  and postoperative infection were commonly 
observed in most cases of single-drug and multiple drug 
combination therapies with each of the drugs that affect 
the immune system.  The FDA and past studies have 
reported that there is a high risk of developing MRONJ 
with single-drug treatments of BP or anti-RANKL drugs,  
and with combination-drug treatments of bevacizumab 
or sunitinib with BP/anti-RANKL drugs [4 , 5 , 8 ,13 ,14].  
As in earlier reports,  in the present study,  delayed 
wound healing and ONJ were observed with not only 
angiogenesis inhibitors,  but also drugs such as 
DMARDs (methotrexate,  etc. ),  immunosuppressants,  
and biological agents [4 , 5 , 8 , 12 , 16-22].  Dental treat-
ments require a careful approach,  since there may be 
drugs other than those with an FDA warning that pose 
a risk of delayed wound healing and ONJ.
As for the period of onset of complications associ-
ated with dental treatments,  the majority of postopera-
tive wound infections and delayed wound healing 
occurred within less than 1 month,  whereas a large 
number of ONJ cases occurred at 1 month.  Pimolbutr 
et al.  reported that MRONJ after tooth extraction 
developed during a period of 3 months,  and a similar 
tendency was observed in the present study [13].  In 
terms of the use of antibiotics,  the majority of patients 
undergoing invasive dental treatment,  such as tooth 
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extraction,  were given antibiotics.  The majority of cases 
used penicillin- and cephalosporin-based antibiotics,  
and their use was considered appropriate based on the 
guideline for preventing postoperative infection pub-
lished by the Japanese Society of Chemotherapy and 
Japan Society for Surgical Infection [Japanese Society of 
Chemotherapy : http://www.chemotherapy.or.jp/
guideline/ jyutsugo_shiyou_jissen.pdf].
Only about 18% of the dentists contacted the attend-
ing physician to request the temporary discontinuation 
of these drugs affecting the immune system prior to the 
dental treatments.  A previous questionnaire survey that 
targeted physicians reported that approximately 60% of 
respondents had received discontinuation requests from 
dentists,  and they had seen 30 adverse events.  About 
16% of respondents had patients who discontinued 
osteoporosis treatment following a requested drug dis-
continuation.  Moreover,  dentists requested discontin-
uation for many medications that were not associated 
with the incidence of ONJ [10].  According to the posi-
tion paper on MRONJ,  there is no evidence that the 
discontinuation of drugs before dental treatment inhib-
its the development of ONJ [4 , 5].  Thus,  there were 
very few requests for the discontinuation of BPs and 
anti-RANKL drugs,  but requests to discontinue other 
drugs were made by some dentists (18% of respon-
dents),  which was similar to the finding in the previous 
questionnaire survey [4 , 5 , 10].  Education on manage-
ment policies in regard to these drugs is necessary for all 
dentists when dental treatments are necessary.
When drugs were discontinued,  the most prevalent 
discontinuation periods were 1-4 months prior to and 
1-3 months after the procedures,  almost the same as in 
the previous report [10].  In the majority of cases,  the 
drugs were re-introduced,  perhaps because of the posi-
tion paper on MRONJ pertaining to drug discontinua-
tion,  which outlines that drug discontinuation should 
occur 2 months before and administration should 
resume 2 months after dental treatments [4 , 5].  On the 
other hand,  the drugs were not discontinued in over 
50% of the cases; this was because a majority of the 
respondents were OMSs who could easily collaborate 
with physicians in the hospital.  A previous study sug-
gested that a long waiting period (≥ 2 months) before 
tooth extraction for stopping the antiresorptive medica-
tions may be a risk factor for delayed wound healing 
beyond 8 weeks after extraction in osteoporosis patients 
≥ 60 years of age [23].  Similar to the situation of BPs 
and anti-RANKL drugs in relation to ONJ,  many den-
tists did not discontinue the drugs in their patients with 
MRONJ,  taking into account the adverse effects of drug 
discontinuation on the primary disease.  While there 
were not many,  some serious adverse events were seen 
during the drug discontinuation period,  such as a 
worsening of rheumatism,  enlarged tumors,  and rejec-
tion reactions of transplanted organs.  Since a previous 
questionnaire survey that targeted physicians reported 
that the respondents experienced 30 adverse events,  
including 10 fractures,  1 ONJ,  and 4 cases of worsen-
ing symptoms [10],  a careful approach to drug discon-
tinuation is necessary.
With respect to medical-dental cooperation,  about 
half of the dentists were approached by physicians to 
discuss oral hygiene management prior to starting 
treatment with these drugs that affect the immune sys-
tem.  Approximately 85% of the dentists said that they 
were already cooperating with physicians,  or that they 
were planning to do so.  A questionnaire survey that 
targeted physicians reported that approximately 76% of 
respondents had never requested oral health care from 
dentists before osteoporosis treatment [10],  which was 
different from our present result.  The reported study 
was published in 2014,  and cooperation between dental 
and medical professionals may have improved in the 
ensuing 5 years.  However,  72% of respondents reported 
that there is no cooperation between dentists and med-
ical professionals in their region,  which would corre-
spond with the incidence in the present study (the 
existence of cooperation with physicians remained at 
about 35% in the community) [10].  About 70% of the 
dentists had been asked by their patients about compli-
cations associated with dental treatments when under-
going therapy with these drugs,  confirming that the risk 
of complications with these drugs is widely known.  In 
the future,  dentists will need to promote medical coop-
eration and dissemination of information in the com-
munity in regard to drugs,  other than antiresorptive 
agents,  that confer a risk of developing MRONJ.
A limitation of the present study was the fact that 
this was a questionnaire survey with a low response rate 
(10.1%).  The low response rate may have been due to 
the large number of items in the questionnaire and the 
need to provide detailed information for each response.  
However,  the dentists’ awareness of and experience 
with adverse events associated with dental treatment in 
patients receiving drugs that affect the immune system 
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were clarified.  In the future,  the Society as a whole will 
need to conduct an investigation of actual conditions 
through the prospective enrollment of cases.
In conclusion,  the present questionnaire survey 
showed that most dentists were aware of the possibility 
of complications associated with dental treatment in 
patients undergoing therapy with drugs that affect the 
immune system.  Nearly half of the dentists had actually 
seen these complications.  Delayed wound healing,  
osteonecrosis of the jaw (ONJ),  and postoperative 
infections were mainly reported.  It was also found that 
the majority of dentists were undertaking dental treat-
ments in cooperation with physicians.  However,  the 
level of cooperation among dentists and physicians in 
the community was low.  Thus,  there is a need for den-
tists to provide sufficient information to physicians 
about dental and medical cooperation.
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